Clinical trial
Basiliximab in Moderate to Severe Ulcerative Colitis
NCT00430898 · Cerimon Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00430898 |
|---|---|
| Title | Basiliximab in Moderate to Severe Ulcerative Colitis |
| Official title | A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of Basiliximab, With Concomitant Corticosteroids, in Steroid-Refractory Ulcerative Colitis |
| Lead sponsor | Cerimon Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ulcerative Colitis |
| Intervention type | Drug |
| Interventions | Basiliximab |
| Enrollment | 181 |
| Start date | Jan 1, 2007 |
| Primary completion | Sep 1, 2008 |
| Completion | Sep 1, 2008 |
| First posted | Feb 2, 2007 |
| Last update posted | Dec 18, 2008 |
| Countries | Belgium, Czechia, India, Poland, Russia, Slovakia, Ukraine, United Kingdom, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: